The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

With sales of Immunocore’s melanoma medicine steadily ticking up and an expanded label likely down the line, CEO Bahija ...

One month after Integra LifeSciences recalled its wound and burn devices amid safety concerns, the medtech company is cutting ...

Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025 and what they suggest about the ...

For millions of Americans with essential tremor, simple tasks like writing a note, putting on makeup or plugging in an appliance can be difficult. | For millions of Americans with essential tremor, ...

"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...